Cargando…
Changes in imatinib plasma trough level during long-term treatment in patients with intermediate- or high-risk gastrointestinal stromal tumors: Relationship between covariates and imatinib plasma trough level
BACKGROUND: Imatinib is the first-line adjuvant treatment for gastrointestinal stromal tumors (GISTs). Considering that some studies have suggested that imatinib (IM) plasma trough levels (C(min)) change with time, the aim of this study is to assess the changes in IM C(min) in patients with GIST in...
Autores principales: | Wu, Xingye, Ge, Yinggang, He, Xuemei, Li, Juan, Zhang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995696/ https://www.ncbi.nlm.nih.gov/pubmed/36911619 http://dx.doi.org/10.3389/fsurg.2023.1115141 |
Ejemplares similares
-
Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients
por: Pursche, Stefan, et al.
Publicado: (2008) -
Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients
por: Omran, Mervat M., et al.
Publicado: (2020) -
Prediction for
Plasma Trough Concentration and Optimal
Dosing of Imatinib under Multiple Clinical Situations Using Physiologically
Based Pharmacokinetic Modeling
por: Gao, Dongmei, et al.
Publicado: (2023) -
Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
por: Yoon, Shinkyo, et al.
Publicado: (2013) -
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
por: Widmer, N, et al.
Publicado: (2008)